Eisai Drops Perampanel In Parkinson’s, Plans First Neuropathy Submission For 2010
This article was originally published in PharmAsia News
Executive Summary
Eisai announced April 11 it has abandoned development of its novel AMPA receptor antagonist perampanel in Parkinson's disease after a second Phase III trial failed, but the Tokyo firm is forging ahead with the compound in other neurological indications
You may also be interested in...
Eisai's Perampanel Shows Positive Phase III Results For Epilepsy Following Failure As Parkinson's Treatment
TOKYO - Positive Phase III results in epilepsy for the AMPA receptor antagonoist perampanel set it on a rebound following Eisai's decision two years ago to abandon development of the drug in Parkinson's disease
Eisai's Perampanel Shows Positive Phase III Results For Epilepsy Following Failure As Parkinson's Treatment
TOKYO - Positive Phase III results in epilepsy for the AMPA receptor antagonoist perampanel set it on a rebound following Eisai's decision two years ago to abandon development of the drug in Parkinson's disease
Eisai's Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson's Disease
Eisai has pushed back the filing of its novel AMPA receptor antagonist perampanel for Parkinson's disease from fiscal 2007 to fiscal fourth quarter 2008 (ended March 31, 2009) in the U.S. and Europe because the drug failed to show an efficacy benefit over placebo in a Phase III study, Eisai said Oct. 30